Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

Germany's Robert Koch Institute (RKI) for infectious diseases has declared the country's RSV wave officially over. RSV, or ...

A monoclonal antibody -- a protein created in a lab which mimics the work of a natural antibody -- could be highly effective ...

Action News anchor Vanessa Vasconcelos sat down with Emergency Physician Doctor Rais Vohra to talk about viruses like the Flu ...

Each year, approximately 177,000 adults aged 65 and older are hospitalized in the United States due to RSV, and an estimated ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations were $-2.92. Operator: Good day, and thank you for standing by. Welcome to ...

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

Dr Reddy’s Laboratories on Monday said it has expanded its strategic partnership with French biopharma giant Sanofi’s Indian ...

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.